Scott N Gettinger
Overview
Explore the profile of Scott N Gettinger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
65
Citations
20202
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gettinger S, Song Z, Reckamp K, Moscow J, Gray R, Wang V, et al.
JCO Precis Oncol
. 2024 Jul;
8:e2300725.
PMID: 38986051
Purpose: National Cancer Institute-Molecular Analysis for Therapy Choice (NCI-MATCH) was a multicohort phase 2 trial that assigned patients with advanced pretreated cancers to molecularly targeted therapies on the basis of...
2.
Schoenfeld A, Lee S, Doger de Speville B, Gettinger S, Hafliger S, Sukari A, et al.
Cancer Discov
. 2024 Apr;
14(8):1389-1402.
PMID: 38563600
In this phase 2 multicenter study, we evaluated the efficacy and safety of lifileucel (LN-145), an autologous tumor-infiltrating lymphocyte cell therapy, in patients with metastatic non-small cell lung cancer (mNSCLC)...
3.
Lee S, Fan W, Wang A, Vaidya R, Redman M, Gettinger S, et al.
JCO Clin Cancer Inform
. 2023 Apr;
7:e2200165.
PMID: 37084329
Purpose: Clinical trial adverse event (AE) data are increasingly complex and high-dimensional, especially for trials evaluating novel targeted agents and immunotherapies. Standard approaches to summarize and analyze AEs remain generally...
4.
Unger J, Qian L, Redman M, Tavernier S, Minasian L, Sigal E, et al.
J Natl Cancer Inst
. 2023 Jan;
115(4):437-446.
PMID: 36625510
Background: An important issue for patients with cancer treated with novel therapeutics is how they weigh the effects of treatment on survival and quality of life (QOL). We compared QOL...
5.
Gettinger S, Huber R, Kim D, Bazhenova L, Hansen K, Tiseo M, et al.
JTO Clin Res Rep
. 2022 Sep;
3(9):100385.
PMID: 36065449
Introduction: We report brigatinib long-term efficacy and safety from phase 1/2 and phase 2 (ALTA) trials in -rearrangement positive (+) NSCLC. Methods: The phase 1/2 study evaluated brigatinib 30 to...
6.
Kim D, Gadgeel S, Gettinger S, Riely G, Oxnard G, Mekhail T, et al.
JTO Clin Res Rep
. 2022 Jul;
3(8):100367.
PMID: 35875467
Introduction: Alectinib is a preferred first-line treatment option for advanced -positive NSCLC. Combination regimens of alectinib with immune checkpoint inhibitors are being evaluated for synergistic effects. Methods: Adults with treatment-naive,...
7.
Wu X, Uhlig J, Blasberg J, Gettinger S, Suh R, Solomon S, et al.
J Vasc Interv Radiol
. 2022 May;
33(8):964-971.e2.
PMID: 35490932
Purpose: To assess the cost effectiveness of microwave ablation (MWA) and stereotactic body radiotherapy (SBRT) for patients with inoperable stage I non-small cell lung cancer (NSCLC). Materials And Methods: A...
8.
Camidge D, Kim H, Ahn M, Yang J, Han J, Hochmair M, et al.
J Thorac Oncol
. 2021 Sep;
16(12):2091-2108.
PMID: 34537440
Introduction: In the phase 3 study entitled ALK in Lung cancer Trial of brigAtinib in 1st Line (ALTA-1L), which is a study of brigatinib in ALK inhibitor-naive advanced ALK-positive NSCLC,...
9.
Gettinger S, Redman M, Bazhenova L, Hirsch F, Mack P, Schwartz L, et al.
JAMA Oncol
. 2021 Jul;
7(9):1368-1377.
PMID: 34264316
Importance: Nivolumab plus ipilimumab is superior to platinum-based chemotherapy in treatment-naive advanced non-small cell lung cancer (NSCLC). Nivolumab is superior to docetaxel in advanced pretreated NSCLC. Objective: To determine whether...
10.
Bewersdorf J, Parmar N, Israel G, Gettinger S, Lee A
J Thromb Thrombolysis
. 2021 Mar;
52(3):854-862.
PMID: 33765243
Cancer patients have a high risk of thromboembolic events including splenic infarct (SI). However, risk factors for SI in cancer patients are poorly understood, and the utility of systemic anticoagulation...